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INVITED COMMENTARY
All we ever wanted to know about perioperative bleeding
Donat R. Spahn and Rolf Rossaint
European Journal of Anaesthesiology 2013, 30:267–269
In this issue of the Journal, the European Society of
Anaesthesiology’s (ESA) guidelines on the management
of severe perioperative bleeding are published.1 These
guidelines are part of the ESA’s efforts to increase patient
safety as declared in the ‘Helsinki Declaration on Patient
Safety in Anaesthesiology’,2 and they are the result of
more than 2 years of hard work by the task force led by
Sibylle Kozek-Langenecker who was mandated by the
ESA in 2010.
These guidelines are massive. They comprise 221
recommendation statements, explanations on approxi-
mately 70 pages, list 1466 references and cover the
following topics: coagulation monitoring; anaemia and
coagulation management; multimodal approaches in
specific clinical fields; anticoagulation and antiplatelet
therapy; and perioperative bleeding management in
patients with comorbidities affecting haemostasis or
with congenital bleeding disorders. So this is all we ever
wanted to know about perioperative bleeding manage-
ment! We, therefore, encourage everybody to read these
guidelines carefully; but can they be read in the same
way that we review scientific papers normally? Probably
not, because the manuscript is huge and discusses 221
individual issues, but does not provide simple algorithms
on how to handle a bleeding case in daily clinical practice.
Nevertheless, these guidelines are a valuable source of
information for those anaesthesiologists with a particular
interest in perioperative bleeding and coagulation.
For these individuals, these guidelines should be the
basis upon which they create algorithms on how to treat
patients in specific situations at their hospitals3,4 as well
as for educational initiatives. Such local educational
programmes and algorithms are vital to transform the
knowledge provided within the guidelines into outcome
benefits for patients suffering from major bleeding. This
is indeed possible as the example of Gorlinger et al.
shows.4 They created such algorithms (which were based
on near patient testing with rotational thromboelastome-
try) for the individual, specific treatment of coagulation
derangements with coagulation factor concentrates
and labile blood products. Moreover, they analysed the
outcome of patients undergoing cardiac surgery at the
Essen University Hospital before and after algorithm
implementation between 2004 and 2009. Not only were
they able to substantially decrease the number of trans-
fusions of red blood cells and fresh frozen plasma, they
also managed to reduce by 50% the incidence of massive
transfusion, take-backs and thrombotic complications.4
Creating such algorithms or treatment pathways is not
only a demand of the Helsinki Declaration on Patient
Safety in Anaesthesiology,2 but also a recommendation of
the second update of the European Trauma Treatment
Guidelines.5 In this latter set of guidelines, the authors
also recommend the creation of checklists in order to
facilitate the consequent implementation of these treat-
ment pathways and a regular assessment of adherence to
these institutional algorithms in routine quality manage-
ment.5 Numerous analyses have shown that adherence
to institutional algorithms results in more consistent
care and improved outcomes for trauma patients,6 and
conversely, major deviation from algorithms results in a
three-fold increase in mortality.7 Physicians, therefore,
do have an obligation to implement such treatment
algorithms. To create a higher awareness for this need,
the ‘STOP the Bleeding Campaign’ was founded.8 This
campaign aims to reduce the number of trauma patients
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dying within 24 h after arrival into hospital due to
exsanguination by a minimum of 20% within the next
5 years.
There is another challenge facing such guidelines;
namely the need to be updated regularly. This is particu-
larly important in fields such as coagulation monitoring,
trauma-induced coagulopathy and the management of
perioperative bleeding, in which new developments are
occurring rapidly. After the initial publication of the first
European Trauma Treatment Guidelines in 2007,9 a first
update was published in 2010,10 with a second update
in 2013,5 and some of the recommendations have signifi-
cantly changed. This is also true for the ESA Guidelines
on the management of severe perioperative bleeding;
fortunately, a regular update is planned.1
The last update of the literature search for the ESA
guidelines was in May 2012 and in the meantime
some highly important papers in the field of active
bleeding have been published. Carson et al.11 published
a Cochrane meta-analysis of 19 prospective randomised
studies comparing the effect of liberal vs. restrictive
haemoglobin transfusion triggers in more than 6000
patients. They found that a restrictive transfusion
strategy resulted in significantly reduced hospital
mortality (23%) and fewer postoperative infections
(19%). Carson et al. undertook this meta-analysis after
they found that in their own prospective randomised trial
(involving elderly patients with acute hip fracture and
known coronary artery disease) a restrictive transfusion
trigger of symptomatic anaemia or haemoglobin less
than 8 g dl1 resulted in a mortality of 6.6% vs. a mortality
of 7.6% (not significant) for patients with a liberal
transfusion trigger of less than 10 g dl1.12 Earlier this
year another important prospective randomised trial in
acute upper gastrointestinal bleeding was published by
Villanueva et al.13 A more restrictive haemoglobin trans-
fusion trigger (<7 vs. <9 g dl1) again resulted in a lower
45-day mortality, lower rates of rebleeding and a shorter
hospital length of stay. Finally, in cardiac surgery, LaPar
et al.14 showed that the introduction of institutional
transfusion guidelines per se resulted in a highly signifi-
cant reduction in blood transfusions and a 45% reduction
in overall hospital mortality. In summary, these high
quality studies confirm that restrictive transfusion
triggers, as recommended by the ESA Guidelines,1 do
indeed reduce mortality in patients bleeding from ortho-
paedic, cardiac and general surgery and in patients with
acute upper gastrointestinal bleeding.
Within the field of trauma care, several highly important
papers have also recently been published. Inaba et al.15
showed that the lower the fibrinogen concentration
at ICU admission, the higher the in-hospital mortality.
Interestingly, patients with normal fibrinogen concen-
trations (>1.8 g l1) had the lowest mortality. This finding
is in keeping with the fibrinogen concentration target
range of 1.5 to 2.0 g l1 recommended by the ESA guide-
lines1 and the European Trauma Treatment Guidelines.5
The importance of early tranexamic acid and fibrinogen
administration [in the form of cryoprecipitate in the
Military Application of Tranexamic Acid in Trauma
Emergency Resuscitation (MATTERs II) study] has been
highlighted in two recent papers.16,17 In military trauma, it
was shown that the early administration of tranexamic acid
and fibrinogen both independently decreased mortality.17
Raza et al.18 investigated hyperfibrinolysis in major trauma
patients and demonstrated that the incidence of hyper-
fibrinolysis, when solely assessed by rotational throm-
belastometry, was only 5%. However, when using more
sensitive tests such as the plasmin-antiplasmin complex
test, 59% had signs of hyperfibrinolysis. Interestingly,
28-day mortality was 12 times higher in patients with
elevated levels of plasmin-antiplasmin complex as com-
pared to those with normal levels of plasmin-antiplasmin
complex (and thus no evidence of hyperfibrinolysis).
These studies strengthen the recommendations for the
early administration of tranexamic acid and fibrinogen
following trauma.1,5 In addition, they may also have
demonstrated a limitation of the current hyperfibrinolysis
test of rotational thromboelastometry.
The ESA, therefore, is to be congratulated for the
vision to view perioperative bleeding an important
topic and the task force commended for their commit-
ment to create these great guidelines; they represent
a tremendous collection of information. To help the
clinicians in their individual institutions to translate
this complex information into practical algorithms,
the various national societies could create examples
of treatment algorithms for the victims of massive haemor-
rhage. An example of this are those just published by the
German Society of Anaesthesiology and Intensive Care.19
We have, therefore, not yet reached our ultimate goal,
which is an improved outcome for patients suffering from
major bleeding. This requires a never-ending educational
effort, the creation and implementation of institutional
guidelines and algorithms, a regular assessment of adher-
ence to these algorithms and the follow-up of the patients
treated to allow the measurement of long-term outcomes.
For specific questions to be answered, further clinical
studies will need to be conducted. In this sense, the
journey towards the optimal management of the bleeding
patient has only just begun.
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